SCHEMBL3345472

SCHEMBL3345472

CC(N)(CC(=O)O)C(=O)c1ccccc1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP2C19 P33261 3/20 0.50
HIF1A Q16665 1/20 0.50
CES1 P23141 6/20 0.45
SRC P12931 1/20 0.42
HSD17B10 Q99714 3/20 0.40
TDP1 Q9NUW8 3/20 0.40
MAPT P10636 3/20 0.40
TSHR P16473 3/20 0.40
CYP3A4 P08684 3/20 0.40
POLB P06746 2/20 0.40
PARP1 P09874 1/20 0.40
RECQL P46063 1/20 0.40
BLM P54132 1/20 0.40
PMP22 Q01453 1/20 0.40
L3MBTL1 Q9Y468 1/20 0.40
NR4A2 P43354 1/20 0.39
ALDH1A1 P00352 2/20 0.39
CYP1A2 P05177 1/20 0.39
CYP2D6 P10635 1/20 0.39
KMT2A Q03164 3/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9076470 0.82 CES1 (0.47) CYP2C19CES1SRCHSD17B10TDP1
SCHEMBL5695380 0.81 CES1 (0.45) CYP2C19HIF1ACES1SRCHSD17B10
SCHEMBL9559864 0.81 CES1 (0.45) CYP2C19HIF1ACES1SRCHSD17B10
SCHEMBL3128833 0.81 CES1 (0.45) CYP2C19HIF1ACES1SRCHSD17B10
SCHEMBL6400748 0.80 CYP2C19 (0.53) CYP2C19HIF1ACES1SRCHSD17B10
Hydrochloric Acid SCHEMBL317256 0.79 CES1 (0.44) CYP2C19HIF1ACES1SRCHSD17B10
SCHEMBL3128812 0.79 CES1 (0.44) CYP2C19CES1SRCHSD17B10TDP1
SCHEMBL3349734 0.78 CES1 (0.47) CYP2C19HIF1ACES1SRCHSD17B10
SCHEMBL4881466 0.78 HIF1A (0.52) CYP2C19HIF1ACES1SRCHSD17B10
SCHEMBL9559908 0.78 CES1 (0.47) CYP2C19HIF1ACES1SRCHSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100105681-A1 2,6-QUINOLINYL AND 2,6-NAPHTHYL DERIVATIVES, PROCESSES FOR PREPARING THEM AND THEIR USES AS VLA-4 INHIBITORS LASSOIE MARIE-AGNES 2010-04-29 US disclosed
US-7638630-B2 Very Late Antigen-4 dependent inflammatory disease; asthma, allergic rhinitis, sinusitis, conjunctivitis, food allergy, inflammatory skin disorders, autoimmune disorders, or atherosclerosis, inflammatory skin disorder; methyl 3-[2-(2,6-dichlorophenyl)-6-quinolinyl]-2-hydroxy-2-propenoate UCB PHARMA S.A. (BE) 2009-12-29 US disclosed
US-20080064720-A1 2,6-Quinolinyl And 2,6-Naphthyl Derivatives, Processes For Preparing Them And Their Uses As Vla-4 Inhibitors UCB, S.A. (BE) 2008-03-13 US disclosed
WO-1999020606-A2 PIPERIDINES AND PIPERAZINES AS PLATELET AGGREGATION INHIBITORS J. URIACH & CIA. S.A. (ES) 1999-04-29 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080064720-A1 2,6-Quinolinyl And 2,6-Naphthyl Derivatives, Processes For Preparing Them And Their Uses As Vla-4 Inhibitors VCAM1, HRH4, LTA4H CYP2C19 468/4885HIF1A 2406/4885CES1 960/4885
US-20100105681-A1 2,6-QUINOLINYL AND 2,6-NAPHTHYL DERIVATIVES, PROCESSES FOR PREPARING THEM AND THEIR USES AS VLA-4 INHIBITORS SCN4A, NECTIN4, VPS4B CYP2C19 504/4885HIF1A 3415/4885CES1 628/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.